ACRO hosts Congressional Briefing on clinical research advancements
On Wednesday, October 23, 2019, ACRO hosted a Congressional Briefing on Capitol Hill. With the help of the Congressional Research & Development Caucus, a panel of clinical research experts and leaders was able to educate congressional offices on the advancements clinical research and technology companies are making in drug development. The conversation focused on how ACRO members are driving 21st-century innovation in clinical trials through advancements such as real-world data and evidence, AI and novel patient-centered trial designs.
“Since the passage of the 21st Century Cures Act in 2016, the clinical research industry has seen great advancements in the way clinical trials are designed and run,” said ACRO’s Executive Director Doug Peddicord, he moderated the panel. “Industry leaders are pushing to use innovative methods to assist in bringing molecules to market that will help patients faster.”
The expert panelists included Jeff Allen, President and CEO of Friends of Cancer Research; Ari Feldman, Vice President of Global Compliance and Strategy at Medidata; Amrit Singh, Vice President of Global Infrastructure and Strategy at Bioclinica and Cyndi Verst, President of Design and Delivery Innovation, for the Research & Development Solutions organization at IQVIA.
“Technology should be able to make the patient’s experience better, enable better science, and hopefully bring more efficiency to clinical trials,” said Ari Feldman, Vice President of Global Compliance and Strategy at Medidata during the briefing. “We look forward to working together to press for innovative ways to integrate technology with the drug development process.”
To learn more about innovations and advancements in the clinical trial industry, read ACRO’s recent research on RQBM impacts.